Factor Therapeutics Ltd - FTT share price
About Factor Therapeutics Ltd
Factor Therapeutics Limited, formerly Tissue Therapies Limited, is a biotechnology company. The Company's principal activities include the development and commercialization of its intellectual property in wound care. The Company's lead program, VF-001, is a biologic product for wound care. VF-001 can be used in conjunction with standard care compression bandaging in the community setting. VF-001 is a fusion protein between a truncated vitronectin peptide and Insulin-like growth factor 1(IGF-1). The initial indication for VF-001 is for Venous Leg Ulcers (VLUs). The Company also has other programs in early development to address other wound applications, as well as new products in the ocular wound care space. Its pipeline includes VF-002, a viscous product to assess burn potential, particularly mucosal burns from radiation therapy, and VF-003 and VF-004, for growth in eye procedures/use of glaucoma stents, reduction of fibrosis and minimization of negative effects of ocular surgery.
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Try Veye Free for 7 Days
Expert ASX stock picks, in-depth research & buy/sell signals — free for a full week.
No credit card required
Price Chart (FTT)
TOP ASX STOCKS Worth Watching
- ✓ Instant Access
- ✓ No Credit Card Required
- ✓ Free to join · No spam
Free to join · No spam · Unsubscribe anytime
By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.
Discover the Top ASX Stocks to Invest in 2026!
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Other Reports from Veye
Latest Article